The report was reviewed by individuals chosen for their diverse perspectives and technical expertise in accordance with procedures approved by the National Research Council’s Report Review Committee. The purpose of this independent review is to provide candid and critical comments to assist the authors and the Institute of Medicine in making the published report as sound as possible and to ensure that the report meets institutional standards for objectivity, evidence, and responsiveness to the study charge. The content of the review comments and the draft manuscript remain confidential to protect the integrity of the deliberative process. The committee wishes to thank the following individuals for their participation in the report review process:
Bernard A. Schwetz, Acting Deputy Commissioner of Food and Drugs, Food and Drug Administration, Rockville, Maryland
Hugh Tilson, Liaison to the Board on Health Promotion and Disease Prevention; Senior Advisor to the Dean, School of Public Health, University of North Carolina, Global Health Outcomes, Glaxo Wellcome Company
Mel Worth, M.D., Scholar-in-Residence, Institute of Medicine, Washington, D.C.
While the individuals listed above provided many constructive comments and suggestions, responsibility for the final content of the report rests solely with the authoring committee and the Institute of Medicine.